HK1255584A1 - 使用阿坎酸及d-環絲胺酸的聯合療法 - Google Patents

使用阿坎酸及d-環絲胺酸的聯合療法

Info

Publication number
HK1255584A1
HK1255584A1 HK18114711.9A HK18114711A HK1255584A1 HK 1255584 A1 HK1255584 A1 HK 1255584A1 HK 18114711 A HK18114711 A HK 18114711A HK 1255584 A1 HK1255584 A1 HK 1255584A1
Authority
HK
Hong Kong
Prior art keywords
acamprosate
cycloserine
combination therapy
therapy
combination
Prior art date
Application number
HK18114711.9A
Other languages
English (en)
Inventor
Steven L Johns
Craig A Erickson
Original Assignee
Confluence Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Confluence Pharmaceuticals Llc filed Critical Confluence Pharmaceuticals Llc
Publication of HK1255584A1 publication Critical patent/HK1255584A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK18114711.9A 2015-08-04 2018-11-16 使用阿坎酸及d-環絲胺酸的聯合療法 HK1255584A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200864P 2015-08-04 2015-08-04
PCT/US2016/045547 WO2017024129A1 (en) 2015-08-04 2016-08-04 Combination therapy using acamprosate and d-cycloserine

Publications (1)

Publication Number Publication Date
HK1255584A1 true HK1255584A1 (zh) 2019-08-23

Family

ID=57944041

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114711.9A HK1255584A1 (zh) 2015-08-04 2018-11-16 使用阿坎酸及d-環絲胺酸的聯合療法

Country Status (11)

Country Link
US (2) US20180221315A1 (zh)
EP (1) EP3331518A4 (zh)
JP (2) JP2018526345A (zh)
KR (1) KR20180034442A (zh)
AU (2) AU2016303610A1 (zh)
CA (1) CA2993614A1 (zh)
HK (1) HK1255584A1 (zh)
IL (1) IL257035A (zh)
SG (1) SG10201914045QA (zh)
WO (1) WO2017024129A1 (zh)
ZA (1) ZA201800558B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024129A1 (en) * 2015-08-04 2017-02-09 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and d-cycloserine
KR20200005576A (ko) 2017-05-17 2020-01-15 컨플루언스 파마슈티컬스, 엘엘씨 호모타우린 및 이의 염의 제형
JP7308761B2 (ja) 2017-05-25 2023-07-14 グリテック, エルエルシー Nmdarアンタゴニスト-応答性精神神経障害のための併用療法
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
WO2023171106A1 (ja) * 2022-03-08 2023-09-14 ソシウム株式会社 Tdp-43の凝集の抑制剤、tdp-43が過剰発現している細胞の細胞死の抑制剤、及びtdp-43の凝集を伴う疾患の治療又は予防剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2167068A2 (en) * 2007-07-05 2010-03-31 Inserm-Institut National De La Sante Et De La Recherche Medicale Anticonvulsive pharmaceutical compositions
PT2395990E (pt) * 2009-02-12 2015-02-09 Univ Indiana Res & Tech Corp Material e métodos de tratamento de transtornos do desenvolvimento incluindo autismo comórbido e idiopático
US20100216805A1 (en) * 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5893135B2 (ja) * 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
SG11201708393UA (en) * 2015-05-04 2017-11-29 Confluence Pharmaceuticals Llc Sprinkle formulations of acamprosate
WO2017024129A1 (en) * 2015-08-04 2017-02-09 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and d-cycloserine

Also Published As

Publication number Publication date
AU2016303610A1 (en) 2018-02-01
US20200360316A1 (en) 2020-11-19
WO2017024129A1 (en) 2017-02-09
IL257035A (en) 2018-03-29
EP3331518A1 (en) 2018-06-13
SG10201914045QA (en) 2020-03-30
JP2021152060A (ja) 2021-09-30
KR20180034442A (ko) 2018-04-04
ZA201800558B (en) 2019-10-30
US20180221315A1 (en) 2018-08-09
EP3331518A4 (en) 2019-04-03
JP2018526345A (ja) 2018-09-13
AU2022202218A1 (en) 2022-04-21
CA2993614A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
IL263521A (en) Combination therapy
IL258931A (en) Medicinal compounds and methods
IL257976A (en) Combined treatment
GB201516442D0 (en) Combination therapy
IL265406B (en) combined treatment
HK1255110A1 (zh) 組合療法
HK1255584A1 (zh) 使用阿坎酸及d-環絲胺酸的聯合療法
GB201609597D0 (en) Therapy
GB201604318D0 (en) Combination therapy
GB201604316D0 (en) Combination therapy
IL265340A (en) Combination therapy
GB201617470D0 (en) Novel therapy
GB201609735D0 (en) Combination therapy
GB201603653D0 (en) Combination Therapy
GB201618477D0 (en) Therapy
GB201615923D0 (en) Macrophage-based therapy
GB201703070D0 (en) Therapy
GB201609721D0 (en) Cobination therapy
GB201609312D0 (en) Therapy
GB201609322D0 (en) Therapy
GB201613179D0 (en) Combination therapy
GB201609722D0 (en) Combination therapy
GB201609770D0 (en) Combination therapy
GB201609719D0 (en) Combination therapy
GB201609766D0 (en) Combination therapy